Healthcare Industry News: Barrett's esophagus
News Release - August 16, 2007
SpectraScience Appoints Michel Vaudry as Director of International SalesSAN DIEGO, Aug. 16 (HSMN NewsFeed) -- SpectraScience, Inc. (OTC Bulletin Board: SCIE ) announced today that it has appointed Michel Vaudry as its Director of International Sales.
Michel was raised in France and moved from Europe to the US to hold the position of VP International Sales for a major medical device manufacturer. Subsequently, he was the President of Medicare Industries, Inc., manufacturing Intensive Care equipment for neonates. At Medicare Industries, he also headed the Operations and Regulatory/Quality Control Departments and set-up International marketing, manufacturing and research/development alliances. He was also responsible for establishing ISO 9001 and CE marks. Later, he held the position of Technical Director at Hemotherapies, Inc., a Liver Dialysis Manufacturer. Michel has a Bachelor of Science in Electronic Engineering and a Degree in Mechanical Engineering from the University of Caen, Normandy, France. He is fluent in French, English and conversational in Spanish and has some knowledge of spoken Arabic.
SpectraScience has developed a multi-patented and proprietary WavSTAT(TM) Optical Biopsy System that is used by physicians to diagnose tissue to determine if it is normal, pre-cancerous, or cancerous within seconds. The WavSTAT(TM) System is currently approved by the FDA for use in detecting pre-cancer and cancer in the colon. A new application for detecting pre-cancers in the throat, sometimes called Barrett's esophagus, is being tested in a clinical trial. Cancer of the esophagus is more than 90% fatal and may develop as a result of chronic heartburn or GERD. Esophageal cancer is growing five times faster than all other cancers.
This news release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from the results discussed in the forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, the Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.
For further information contact Jim Hitchin at (858) 847-0200. http://www.spectrascience.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.